MiniMed Group, Inc. (MMED)
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-11-04
$19.29+2.33%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - Equipment & ServicesSnapshot 2026-11-04
Research Workspace
Put MMED beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 2% a day.
View RiskMostly healthy — no soft spokes
MiniMed's Flex insulin pump must keep gaining market share to justify the price. Revenue grew 16.6% year over year in the latest quarter. However, the company missed its earnings target by 100%. It trades at 1.8 times sales versus a 3.4 times peer median. This discount reflects modest growth expectations relative to our view. The main risk is that operating losses persist despite the revenue growth. Our model puts the next-quarter miss probability near 48%. Peer multiples imply a price about 66% above where it trades. This read is provisional.
Trailing returns as of 2026-11-04. MMED is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering MMED (as of Nov 2026).
Based on 10 Wall Street analysts offering 12-month price targets for MMED in the last 4 months.
Continue this research
Compare MMED with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| MMED Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 3 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put MMED next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Commercialize MiniMed Flex insulin pump
Analyst upgrade supports commercialization of MiniMed Flex insulin pump.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $19.29
The last 12 months of price, then the range of analyst 12-month targets from today’s $19.29.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Advances: Expand U.S. and international market growth
Analyst upgrade supports market growth expectations.
Threatens: Manage operating losses and improve profitability
Analysts raised targets but cash flow concerns persist.
Advances: Maintain corporate governance and manage executive transitions
Separation enhances focus on MiniMed's growth and governance.
Advances: Commercialize MiniMed Flex insulin pump
New pump lineup enhances commercialization efforts.
Advances: Commercialize MiniMed Flex insulin pump
Stock price target increase indicates strong sales performance.
Advances: Commercialize MiniMed Flex insulin pump
Strong revenue growth supports commercialization of MiniMed Flex insulin pump.
Advances: Commercialize MiniMed Flex insulin pump
Price target increase reflects confidence in product commercialization.
